Studies related to Fatigue and Pelargonium sidoides

Pelargonium Sidoides Preparation (EPs 7630) In The Treatment Of Acute Bronchitis In Adults And Children

Effect Decrease
Trial Design Double blind
Trial Length 1-2 Weeks
Number of Subjects 2023
Gender Both Genders
Age Range 0-1, 1-6, 7-12, 13-17, 18-29, 30-44, 45-64, 65+
Notes for this study:
Two weeks supplementation of EPs7630 to persons of all ages (30 drops thrice daily for adults, but 20 drops thrice daily for those between 6-12 and 10 drops thrice daily for those younger than 6) was able to significantly reduce overall symptoms as assessed by the BSS by around 86% with 68% of the sample reporting more than a 5 point reduction.

Most other comorbidities such as fever, fatigue, and headache were reduced in the range of 80-94.6%. Rhonchi (93.1% remission) chest pain during cough (94.1%), and shortness of breath (93.2%), but cough was only abolished in 56.2% of persons.

Efficacy And Safety Of An Extract Of Pelargonium Sidoides (EPs 7630) In Adults With Acute Bronchitis. A Randomised, Double-blind, Placebo-controlled Trial

Effect Decrease
Trial Design Double blind
Trial Length 1-7 Days
Number of Subjects 468
Gender Both Genders
Age Range 30-44, 45-64
Body Types Average
Notes for this study:
Thirty drops (4.5mL) of Eps7630 thrice daily for a week in adults with acute bronchitis around the time of meals was associated with a greater decrease of overall symptoms as assessed by the BSS rating scale (70% reduction in symptoms) relative to placebo (40%) with symptom reduction occurring in about three days time.

EPs7630 was also more effective at causing an overall rating of less than three on the 10 point rating scale (64.4% relative to 37.9%) and at inducing a 7 point reduction within the week (43.3% relative to 23% in placebo).

After 7 days, there was abolishment of rhonchi (77.1%), coughing (83.8%) fatigue (65.1%), headache (75-81.7%), and fever (96.9%) in treatment, all more than placebo.

Treatment Of Acute Bronchitis In Adults With A Pelargonium Sidoides Preparation (EPs 7630): A Randomized, Double-blind, Placebo-controlled Trial

Effect Decrease
Trial Design Double blind
Trial Length 1-7 Days
Number of Subjects 107
Gender Both Genders
Age Range 18-29, 30-44, 45-64
Body Types Average
Notes for this study:
30 drops (4.5mL) of EPs7630 thrice daily for a week in adults with acute bronchitis was associated with significant reductions in symptoms as assessed by the BSS rating scale. There was also a greater change of a 5 point reduction in the treatment group (90.6%) rather than placebo (51.7%) and reported rapid recovery (90.6% relative to 41.7%); there were significantly more remissions of cough (31.3%), rhonchi (91%)

Treatment Of Acute Bronchitis With A Liquid Herbal Drug Preparation From Pelargonium Sidoides (EPs 7630): A Randomised, Double-blind, Placebo-controlled, Multicentre Study

Effect Decrease
Trial Design Double blind
Trial Length 1-7 Days
Number of Subjects 217
Gender Both Genders
Age Range 18-29, 30-44, 45-64
Body Types Average
Notes for this study:
In adult patients with acute bronchitis given 30 drops of EPs7630 thrice daily for a period of one week, symptoms of acute bronchitis (BSS) was able to increase complete remission on day seven to 45.4% of the treatment group (over 6.4% of the placebo) as assessed by physicians, and 89.8% and 65.1% self-reported complete or major recovery (more 'complete' recovery in treatment). Most marked improvement was in cough, where only 11.9% of placebo reported complete recovery while 51.9% of treatment did after seven days.

Efficacy And Tolerability Of EPs 7630 Tablets In Patients With Acute Bronchitis: A Randomised, Double-blind, Placebo-controlled Dose-finding Study With A Herbal Drug Preparation From Pelargonium Sidoides

Effect Decrease
Trial Design Double blind
Trial Length 1-7 Days
Number of Subjects 404
Gender Both Genders
Age Range 30-44, 45-64
Body Types Overweight
Notes for this study:
Patients with acute bronchitis administered EPs7630 in capsules ranging from 10mg thrice daily to 30mg thrice daily (or placebo) over the course of one week noted that 20mg and 30mg groups were equally effective over placebo while 10mg was sometimes effective over placebo but unreliably so.

EPs 7630-solution--an Effective Therapeutic Option In Acute And Exacerbating Bronchitis

Effect Decrease
Trial Design Double blind
Trial Length 1-7 Days
Number of Subjects 205
Gender Both Genders
Age Range 18-29, 30-44, 45-64
Body Types Average
Notes for this study:
EPs7630 at 30 drops thrice daily in persons with bronchitis (either acute, or chronic bronchitis experienced an exacerbation) over a week was associated with improvements on all symptoms of bronchitis to a level greater than placebo. Symptoms appeared to be improved within 2 days of supplementation, and after 7 days 92.7% of the treatment group reported satisfaction with treatment.

EPs 7630 Improves Acute Bronchitic Symptoms And Shortens Time To Remission. Results Of A Randomised, Double-blind, Placebo-controlled, Multicentre Trial

Effect Decrease
Trial Design Double blind
Trial Length 1-7 Days
Number of Subjects 217
Gender Both Genders
Age Range 18-29, 30-44, 45-64
Body Types Average
Notes for this study:
In adult outpatients with acute bronchitis given the standard 30 drops of EPs7630 thrice daily for a period of seven days, there were significantly improved symptoms on all parameters of the BSS and secondary outcome variables with particular improvement in fatigue and coughs; days off from work was reduced secondary to helping cure acute bronchitis.